Skip to main content
GENETIC TECHNOLOGIES LIMITED logo

GENETIC TECHNOLOGIES LIMITED — Investor Relations & Filings

Ticker · GTG ISIN · AU000000GTG7 LEI · 529900YYKY7FRC90M744 ASX Human health and social work activities
Open in API
Filings indexed 1,303 across all filing types
Latest filing 2023-03-26 Regulatory Filings
Country AU Australia
Listing ASX GTG

About GENETIC TECHNOLOGIES LIMITED

https://gtglabs.com/

Genetic Technologies Limited is a molecular diagnostics company focused on the development and commercialization of predictive genetic risk assessment tools. The company specializes in the geneType platform, which integrates clinical risk factors with polygenic risk scores to provide comprehensive risk assessments for various chronic diseases. Its portfolio includes tests for breast cancer, colorectal cancer, prostate cancer, melanoma, type 2 diabetes, and coronary artery disease. By identifying individuals at high risk of developing these conditions, the company enables healthcare providers to implement personalized screening and preventative health strategies. Genetic Technologies Limited serves clinicians and patients globally, aiming to improve health outcomes through early detection and precision medicine.

Recent filings

Filing Released Lang Actions
GeneType MultiTest Panel Expanded Inclusion of New Diseases 2 pages 216.2KB
Regulatory Filings Classification · 95% confidence The document is an ASX Market Announcement from Genetic Technologies Limited dated 27 March 2023. It announces the expansion of the geneType Multi-Test Panel to include three new diseases. The content focuses on product update and business development rather than financial results, management changes, or regulatory filings. It is a corporate announcement about a product expansion, not a financial report, earnings release, or regulatory filing. The document length is 6259 characters, which is sufficient for a detailed announcement but does not contain financial statements or detailed investor presentation slides. It is not a report publication announcement since it does not mention the release or availability of a report. The document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about a business update that does not fit into other specific categories like earnings, capital update, or management changes.
2023-03-26 English
Response to ASX Query 5 pages 235.9KB
Regulatory Filings Classification · 95% confidence The document is a letter from the Australian Securities Exchange (ASX) to Genetic Technologies Limited (GTG) requesting information and responses regarding a prior announcement made by GTG about a study validating their geneType Breast Cancer Risk Test. The letter references specific ASX Listing Rules (3.1, 3.1A, 18.7) concerning continuous disclosure obligations and market-sensitive information. The content is a regulatory inquiry and response letter about compliance with disclosure rules, not a financial report, earnings release, or management discussion. It is a regulatory filing related to compliance and disclosure matters, not a report or announcement of financial results or corporate governance changes. The document is lengthy (over 14,000 characters) and contains detailed Q&A responses to ASX queries, indicating it is a formal regulatory filing. Therefore, the appropriate classification is Regulatory Filings (RNS).
2023-03-16 English
Further Study Validates geneType Breast Cancer Risk Test 2 pages 212.6KB
Regulatory Filings Classification · 95% confidence The document is an ASX Market Announcement from Genetic Technologies Limited dated March 13, 2023. It announces the publication of a peer-reviewed research paper validating the geneType Breast Cancer Risk Test. The content focuses on scientific validation and clinical utility of a product, referencing recent publications and studies. There is no financial data, earnings information, management discussion, or regulatory filing details. The document is a corporate announcement about research validation and scientific milestones, not a financial report, regulatory filing, or management update. It is not a report publication announcement since it does not mention the release or availability of a report but rather announces a research paper publication. The document fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about company developments that do not fit other specific categories.
2023-03-12 English
Notification of cessation of securities - GTG 4 pages 24.2KB
Regulatory Filings Classification · 95% confidence The document is a notification about the cessation of securities, specifically options that have expired without exercise or conversion. It provides details about the securities that have ceased, the reason for cessation, and the updated issued capital following these changes. The document is an announcement related to changes in the company's securities, not a financial report or detailed analysis. It fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement about securities cessation and does not fall under more specific categories like capital changes (SHA) or share transactions (POS) because it is about cessation due to expiry rather than issuance or repurchase.
2023-03-06 English
Change in substantial holding 5 pages 1.6MB
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 Notice of Change of Interests of Substantial Holder filed under the Corporations Act 2001. It details changes in voting power and relevant interests of a substantial shareholder (The Bank of New York Mellon Corporation and its group entities) in Genetic Technologies Limited. The form includes specifics about previous and present voting power, changes in relevant interests, and associations. This type of filing is a notification of changes in significant share ownership levels, which corresponds to the category Major Shareholding Notification (MRQ). The document is not a financial report, earnings release, or management report, but a regulatory disclosure about shareholding changes.
2023-02-28 English
Half Year Financial Results Investor Webinar Presentation 24 pages 2.4MB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'FY23 Half-year Financial Results – Strong Revenue Growth Performance' and provides detailed financial and operational highlights for the six months ending 31 December 2022. It includes revenue figures, strategic alliances, commercialization plans, scientific publications, and an outlook statement. The document also announces an investor webinar to discuss the half-year results. The content is comprehensive and includes substantive financial data and analysis for a period shorter than a full fiscal year, consistent with an Interim / Quarterly Report. There is no indication that this is merely an announcement or a presentation, but rather a detailed report of half-year financial results and operational performance. H1 2023
2023-02-27 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.